Tanaya Shree1, Qian Li2, Sally L Glaser3, Ann Brunson2, Holden T Maecker4, Robert W Haile5, Ronald Levy1, Theresa H M Keegan2. 1. Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA. 2. Center for Oncology Hematology Outcomes Research and Training (COHORT) and Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, CA. 3. Cancer Prevention Institute of California, Fremont, CA. 4. Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA. 5. Center for Translational Population Sciences, Cedars-Sinai Medical Center, Los Angeles, CA.
Abstract
PURPOSE: Therapeutic advances for diffuse large B-cell lymphoma (DLBCL) have led to an increasing number of survivors. Both DLBCL and its treatments perturb the immune system, yet little is known about immune health during extended survivorship. METHODS: In this retrospective cohort study, we compared 21,690 survivors of DLBCL from the California Cancer Registry (CCR) to survivors of breast, prostate, head and neck, and melanoma cancers. We linked their CCR records to a statewide database documenting hospital, emergency room, and ambulatory surgery visits and investigated the incidence of autoimmune conditions, immune deficiencies, and infections 1-10 years after cancer diagnosis. RESULTS: We found elevated incidence rate ratios (IRRs) for many immune-related conditions in survivors of DLBCL compared with other cancer survivors, including significantly and consistently elevated IRRs for viral and fungal pneumonias (up to 10.8-fold), meningitis (up to 5.3-fold), as well as humoral deficiency (up to 17.6-fold) and autoimmune cytopenias (up to 12-fold). IRRs for most conditions remained high even in the late survivorship period (5-10 years after cancer diagnosis). The elevated risks could not be explained by exposure to chemotherapy, stem-cell transplantation, or rituximab, except for IRRs for humoral deficiency, which were consistently higher after the incorporation of rituximab into DLBCL treatments. CONCLUSION: To our knowledge, this is the largest cohort study with extended follow-up to demonstrate impaired immune health in survivors of DLBCL. The observed persistent, elevated risks for autoimmune diseases, immune deficiencies, and infectious conditions may reflect persistent immune dysregulation caused by lymphoma or treatment and may lead to excess morbidity and mortality during survivorship. Improved understanding of these risks could meaningfully improve long-term care of patients with DLBCL.
PURPOSE: Therapeutic advances for diffuse large B-cell lymphoma (DLBCL) have led to an increasing number of survivors. Both DLBCL and its treatments perturb the immune system, yet little is known about immune health during extended survivorship. METHODS: In this retrospective cohort study, we compared 21,690 survivors of DLBCL from the California Cancer Registry (CCR) to survivors of breast, prostate, head and neck, and melanoma cancers. We linked their CCR records to a statewide database documenting hospital, emergency room, and ambulatory surgery visits and investigated the incidence of autoimmune conditions, immune deficiencies, and infections 1-10 years after cancer diagnosis. RESULTS: We found elevated incidence rate ratios (IRRs) for many immune-related conditions in survivors of DLBCL compared with other cancer survivors, including significantly and consistently elevated IRRs for viral and fungal pneumonias (up to 10.8-fold), meningitis (up to 5.3-fold), as well as humoral deficiency (up to 17.6-fold) and autoimmune cytopenias (up to 12-fold). IRRs for most conditions remained high even in the late survivorship period (5-10 years after cancer diagnosis). The elevated risks could not be explained by exposure to chemotherapy, stem-cell transplantation, or rituximab, except for IRRs for humoral deficiency, which were consistently higher after the incorporation of rituximab into DLBCL treatments. CONCLUSION: To our knowledge, this is the largest cohort study with extended follow-up to demonstrate impaired immune health in survivors of DLBCL. The observed persistent, elevated risks for autoimmune diseases, immune deficiencies, and infectious conditions may reflect persistent immune dysregulation caused by lymphoma or treatment and may lead to excess morbidity and mortality during survivorship. Improved understanding of these risks could meaningfully improve long-term care of patients with DLBCL.
Authors: Byung-Jo Kim; Ha-Rim Park; Hak Jae Roh; Du-Shin Jeong; Byung Soo Kim; Kun-Woo Park; S Charles Cho; Yuen T So; Sung Yong Oh; Seok Jin Kim Journal: Qual Life Res Date: 2010-05-05 Impact factor: 4.147
Authors: Rami S Komrokji; Najla H Al Ali; M S Beg; Malek M Safa; Dana Rollison; Mohamed Kharfan-Dabaja; Celeste Bello; Jennifer Cultrera; Lubomir Sokol; Javier Pinilla-Ibarz; Eduardo M Sotomayor Journal: Clin Lymphoma Myeloma Leuk Date: 2011-04-20
Authors: Beibei Xu; Isabel J Boero; Lindsay Hwang; Quynh-Thu Le; Vitali Moiseenko; Parag R Sanghvi; Ezra E W Cohen; Loren K Mell; James D Murphy Journal: Cancer Date: 2014-12-23 Impact factor: 6.860
Authors: Nadia Howlader; Angela B Mariotto; Caroline Besson; Gita Suneja; Kim Robien; Naji Younes; Eric A Engels Journal: Cancer Date: 2017-05-02 Impact factor: 6.860
Authors: Alison R Walker; Anatole Kleiner; Lynn Rich; Charlene Conners; Richard I Fisher; Jennifer Anolik; Jonathan W Friedberg Journal: Cancer Invest Date: 2008-05 Impact factor: 2.176
Authors: Klaudia U Hunter; Oliver E Lee; Teresa H Lyden; Marc J Haxer; Felix Y Feng; Mathew Schipper; Francis Worden; Mark E Prince; Scott A McLean; Gregory T Wolf; Carol R Bradford; Douglas B Chepeha; Avraham Eisbruch Journal: Head Neck Date: 2013-06-01 Impact factor: 3.147
Authors: Karin Ekström Smedby; Claire M Vajdic; Michael Falster; Eric A Engels; Otoniel Martínez-Maza; Jennifer Turner; Henrik Hjalgrim; Paolo Vineis; Adele Seniori Costantini; Paige M Bracci; Elizabeth A Holly; Eleanor Willett; John J Spinelli; Carlo La Vecchia; Tongzhang Zheng; Nikolaus Becker; Silvia De Sanjosé; Brian C-H Chiu; Luigino Dal Maso; Pierluigi Cocco; Marc Maynadié; Lenka Foretova; Anthony Staines; Paul Brennan; Scott Davis; Richard Severson; James R Cerhan; Elizabeth C Breen; Brenda Birmann; Andrew E Grulich; Wendy Cozen Journal: Blood Date: 2008-02-08 Impact factor: 22.113
Authors: John H Baird; David J Epstein; John S Tamaresis; Zachary Ehlinger; Jay Y Spiegel; Juliana Craig; Gursharan K Claire; Matthew J Frank; Lori Muffly; Parveen Shiraz; Everett Meyer; Sally Arai; Janice Wes Brown; Laura Johnston; Robert Lowsky; Robert S Negrin; Andrew R Rezvani; Wen-Kai Weng; Theresa Latchford; Bita Sahaf; Crystal L Mackall; David B Miklos; Surbhi Sidana Journal: Blood Adv Date: 2021-01-12
Authors: Graça M Dores; Rochelle E Curtis; Nicole H Dalal; Martha S Linet; Lindsay M Morton Journal: J Clin Oncol Date: 2020-09-18 Impact factor: 44.544
Authors: Toby A Eyre; William Wilson; Amy A Kirkwood; Julia Wolf; Catherine Hildyard; Hannah Plaschkes; John Griffith; Paul Fields; Arief Gunawan; Rebecca Oliver; Stephen Booth; Jaimal Kothari; Christopher P Fox; Nicolas Martinez-Calle; Andrew McMillan; Mark Bishton; Graham P Collins; Chris S R Hatton Journal: Blood Adv Date: 2021-04-27